COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland (COUGH)

Bayer

Status: Completed

Conditions: Hypertension

Treatments: Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)

Study type: Observational

Funder types: Industry

Identifiers

NCT01211171

KL0910PL (Other Identifier)

14881

GM.2009-04-06.0017 (Other Identifier)

15379 - KL0910SK (Other Identifier)

Details and patient eligibility

About

In the light of ONTARGET and TRANSCEND studies results, it would be interesting to investigate the real-life telmisartan treatment tolerability. It is well known and accepted that the Real-life setting is much more adequate to reflect the antihypertensive and safety properties of the drug in comparison to the organized and scheduled setting of the clinical trial. Because there are not much data on the cough in relation to telmisartan, therefore it would we worth to observe the cough frequency and general treatment tolerance in patients treated with telmisartan, who had to stop their previous ACE-I treatment due to cough.

Enrollment: 2,498 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: - hypertension

• age > 18
• ACE-I related cough Exclusion Criteria: - Current treatment with telmisartan
• Cholestatic disorders and severe hepatic failure
• Allergy to telmisartan
• Pregnancy and lactation period

Trial design

2,498 participants in 1 patient group

Group 1

Treatment:

Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)